COST-UTILITY ANALYSIS OF ADJUVANT TRASTUZUMAB EMTANSINE VERSUS TRASTUZUMAB IN PATIENTS WITH HER2+EARLY BREAST CANCER WITH RESIDUAL INVASIVE DISEASE AFTER NEOADJUVANT THERAPY IN SPAIN - Colomer, R; Arroyo,; Costa-Samarra, J; Gallego, T (Value In Health, 2020)